FrancophonIA/ELRC3.0 huggingface dataset:
English: The most frequently reported adverse reactions across the entire study period in the study eye of patients who received OZURDEX were cataract and elevated IOP (see below).
Slovenian: Neželena učinka, o katerih so v celotnem obdobju preizkušanja poročali najpogosteje, za preiskovano oko pri bolnikih, ki so prejemali zdravilo OZURDEX, sta bila katarakta in zvišan očesni tlak (glejte spodaj).
English: One sustained release sterile implantable rod shaped implant containing 700 micrograms of dexamethasone, located in the needle (stainless steel) of a disposable applicator.
Slovenian: En sterilni vsadek s podaljšanim sproščanjem v obliki paličice, ki vsebuje 700 mikrogramov deksametazona v igli (iz nerjavnega jekla) aplikatorja za enkratno uporabo.
English: Sham N = 261 P-value
Slovenian: N = 261 p vrednost
English: There is no experience of using OZURDEX in pregnant women or during breast-feeding.
Slovenian: Pri uporabi zdravila OZURDEX pri nosečnicah in doječih materah ni izkušenj.
English: The most frequently reported adverse reactions in the study eye of patients who received OZURDEX were conjunctival haemorrhage (30.3%), increased intraocular pressure (25.0%) and cataract (11.8%).
Slovenian: Neželeni učinki za preiskovano oko pri bolnikih, ki so prejemali zdravilo OZURDEX, o katerih so poročali najpogosteje, so bili krvavitev očesne veznice (30,3 %), zvišan očesni tlak (25,0 %) in katarakta (11,8 %).
English: Whereas, delaying treatment for 6 months results in a lower proportion of responders at all time points in the open label phase when compared with those receiving a second OZURDEX injection.
Slovenian: Zamik zdravljenja za šest mesecev povzroči manjši delež bolnikov z odzivom na vseh časovnih točkah odprte faze v primerjavi z bolniki, ki so prejeli drugo injiciranje zdravila OZURDEX.
English: Discontinuation due to lack of efficacy was lower in the OZURDEX group compared to sham (7% vs 24%).
Slovenian: Prekinitev sodelovanja zaradi neučinkovitosti je bilo manj v skupini, ki je prejela zdravilo OZURDEX, kot v skupini, ki je prejela placebo (7 % in 24 %).
English: Clinical efficacy and safety Diabetic Macular Oedema
Slovenian: Klinična varnost in učinkovitost Diabetični makularni edem
English: Use of corticosteroids, including OZURDEX, may induce cataracts (including posterior subcapsular cataracts), increased IOP, steroid induced glaucoma and may result in secondary ocular infections.
Slovenian: Uporaba kortikosteroidov, vključno z zdravilom OZURDEX, lahko povzroči nastanek katarakt (vključno s posteriornimi subkapsularnimi kataraktami), zvišan očesni tlak, glavkom, ki ga povzročajo steroidi, in sekundarne očesne okužbe.
English: The active substance in OZURDEX is dexamethasone.
Slovenian: Zdravilna učinkovina v zdravilu OZURDEX je deksametazon.
English: - if the eye to be treated has undergone cataract surgery and has a man-made lens, which was implanted in the front compartment of the eye (anterior chamber intraocular lens) or was fixed to the white portion of the eye (sclera) or to the coloured part of the eye (iris), and the back of the lens capsule (“the bag”) has been ruptured
Slovenian: - če je oko, ki naj bi bilo zdravljeno, že bilo operirano za sivo mreno in vsebuje umetno lečo, vstavljeno v sprednji očesni prekat (ACIOL - Anterior Chamber Intraocular Lens) ali pritrjeno na beli del očesa (beločnico) oz. na barvni del očesa (šarenico), in je bila zadnja stran kapsule leče (»vrečke«) natrgana.
English: OZURDEX must be administered by a qualified ophthalmologist experienced in intravitreal injections.
Slovenian: Zdravilo OZURDEX mora injicirati usposobljen oftalmolog z izkušnjami z intravitrealnim injiciranjem.
English: Of the patients experiencing an increase of IOP of ≥10 mmHg from baseline, the greatest proportion showed this IOP increase between 45 and 60 days following an injection.
Slovenian: Pri največjem deležu bolnikov, pri katerih se je očesni tlak zvišal za ≥ 10 mmHg od izhodiščne vrednosti, se je povečanje očesnega tlaka pojavilo od 45 do 60 dni po injiciranju.
English: OZURDEX is used to treat adult patients with:
Slovenian: Zdravilo OZURDEX se uporablja za zdravljenje odraslih bolnikov z naslednjimi stanji:
English: In an in vitro metabolism study, following the incubation of [14C]-dexamethasone with human cornea, iris-ciliary body, choroid, retina, vitreous humour, and sclera tissues for 18 hours, no metabolites were observed.
Slovenian: V študiji presnove in vitro po 18-urni inkubaciji [14C]-deksametazona s človeško roženico, šarenico ciliarnikom, žilnico, mrežnico, steklovino in tkivi beločnice niso opazili nobenih presnovkov.
English: Efficacy in studies 206207-010 and 206207-011 (ITT population)
Slovenian: Preglednica 2.: Učinkovitost v študijah 206207-010 in 206207-011 (populacija, ki so jo nameravali zdraviti)
English: • Active or suspected ocular or periocular infection including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.
Slovenian: • Aktivna očesna ali obočesna okužba ali sum nanjo, vključno z večino virusnih bolezni roženice in očesne veznice, kot so aktivni epitelijski herpesni keratitis (dendritični keratitis), vakcinija, norice, mikobakterijske okužbe in glivične bolezni.
English: • Active or suspected ocular or periocular infection including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis),
Slovenian: • Aktivna očesna ali obočesna okužba ali sum nanjo, vključno z večino virusnih bolezni roženice in očesne veznice, kot so aktivni epitelijski herpesni keratitis (dendritični keratitis), vakcinija,
English: Among patients who did not use anti-coagulant therapy, 27% of OZURDEX treated patients reported haemorrhagic adverse events compared to 20% in the sham group.
Slovenian: Med bolniki, ki niso bili zdravljeni z antikoagulanti, je 27 % bolnikov, zdravljenih z zdravilom OZURDEX, poročalo o neželenih dogodkih s krvavitvijo, v primerjavi z 20 % v kontrolni skupini.
English: No patient required removal of the implant by vitrectomy to control IOP.
Slovenian: Pri nobenem bolniku ni bilo treba zaradi nadzora očesnega tlaka izvesti odstranitve vsadka z vitrektomijo.
English: ** in a 24-month real world observational study in the treatment of macular oedema following RVO and noninfectious uveitis affecting the posterior segment of the eye these adverse events were reported more frequently among patients who received >2 injections vs patients who received ≤2 injections; cataract formation (24.7% vs 17.7%), cataract progression (32.0% vs 13.1%), vitreous haemorrhage (6.0% vs 2.0%), and increased IOP (24.0% vs 16.6%).
Slovenian: ** v 24-mesečni opazovalni študiji v realnem svetu zdravljenja bolnikov z makularnim edemom po okluziji retinalne vene in nenalezljivim uveitisom posteriornega dela očesa so o teh neželenih učinkih pogosteje poročali pri bolnikih, ki so prejeli več kot dve injekciji, v primerjavi z bolniki, ki so prejeli manj kot dve injekciji; nastanek katarakte (24,7 % v primerjavi s 17,7 %), napredovanje katarakte (32,0 % v primerjavi s 13,1 %), vitrealna krvavitev (6,0 % v primerjavi z 2,0 %) ter povišan očesni tlak (24,0 % v primerjavi s 16,6 %)
English: Patients must be instructed to report any symptoms suggestive of endophthalmitis or any of the above mentioned events without delay, e.g. eye pain, blurred vision etc. (see SmPC section 4.8).
Slovenian: Bolnikom je treba naročiti, naj takoj poročajo o kakršnih koli simptomih, ki kažejo na endoftalmitis, ali o katerih koli zgoraj omenjenih dogodkih, npr. bolečini v očesu, zamegljenem vidu ipd. (glejte poglavje 4.8 v Povzetku glavnih značilnosti zdravila).
English: Mean BCVA average change over 3 years, AUC approach (letters)
Slovenian: Srednja povprečna sprememba pri BCVA v 3 letih, pristop AUC (črke)
English: Plasma concentrations were obtained from a subset of 21 patients in the two RVO, 6-month efficacy studies prior to dosing and on days 7, 30, 60 and 90 following intravitreal injection of a single intravitreal implant containing 350 µg or 700 µg dexamethasone.
Slovenian: Koncentracije v plazmi so ugotavljali pri podskupini 21 bolnikov v dveh šestmesečnih študijah učinkovitosti pred odmerjanjem ter na 7., 30., 60. in 90. dan po intravitrealnem injiciranju enega intravitrealnega vsadka, ki je vseboval 350 ali 700 µg deksametazona.
English: 28% of patients treated with OZURDEX had a ≥ 10 mm Hg IOP increase from baseline at one or more visits during the study.
Slovenian: Pri 28 % bolnikov, zdravljenih z zdravilom OZURDEX, je bil očesni tlak pri enem ali več obiskih med preizkušanjem zvišan od izhodiščnega za ≥ 10 mm Hg.
English: With the exception of headache and migraine, no systemic adverse drug reactions were identified with the use of OZURDEX.
Slovenian: Z izjemo glavobola in migrene niso bili zabeleženi nobeni sistemski neželeni učinki uporabe zdravila
English: The percent of patients requiring escape medications from baseline to week 8 was nearly 3-fold less with OZURDEX (7.8%) compared to Sham (22.4%), p = 0.012.
Slovenian: Odstotek bolnikov, pri katerih je bilo treba uporabiti dodatna zdravila, od začetka do 8. tedna, je bil skoraj 3-krat manjši pri zdravljenju z zdravilom OZURDEX (7,8 %) kot pri placebu (22,4 %), p = 0,012.
English: BCVA ≥ 15-letter improvement from baseline at Year 3/Final visit (%)
Slovenian: BCVA ≥ izboljšanje za 15 črk od izhodiščne vrednosti v 3. letu/zadnji obisk (%)
English: In the 3 year DME clinical studies, at baseline, 87% of patients with a phakic study eye treated with OZURDEX had some degree of lens opacification/ early cataract.
Slovenian: V triletnih kliničnih študijah DME se je pri 87 % bolnikov s fakično lečo v preiskovanem očesu, ki so bili zdravljeni z zdravilom OZURDEX, pojavila določena stopnja opacifikacije leče/začetne katarakte.
English: - if you are allergic to dexamethasone or any of the other ingredients of this medicine (listed in section 6) - if you have an infection of any kind in or around your eye (bacterial, viral or fungal) - if you have glaucoma or high pressure inside your eye which is not controlled properly with the medicines you may be using - if the eye to be treated does not have a lens and the back of the lens capsule (“the bag”) has been ruptured
Slovenian: - če imate kakršno koli okužbo v očesu ali okrog njega (bakterijsko, virusno ali glivično); - če imate glavkom ali visok tlak v očesu, ki ga ni mogoče ustrezno nadzorovati z zdravili, ki jih morda uporabljate;
English: The highest plasma concentration value of 0.094 ng/mL was observed in one subject from the 700 µg group.
Slovenian: Največjo koncentracijo v plazmi 0,094 ng/ml so opazili pri enem preizkušancu v skupini z odmerkom 700 µg.
English: As expected with ocular steroid treatment and intravitreal injections, increases in intraocular pressure (IOP) may be seen.
Slovenian: Po pričakovanjih se lahko pri zdravljenju z očesnim steroidom in intravitrealnem injiciranju pojavi zvišanje očesnega tlaka (IOP - intraocular pressure).
English: The plunger is controlled by a lever on the side of the applicator body.
Slovenian: Bat se nadzoruje z vzvodom na stranskem delu aplikatorja.
English: The applicator containing the implant is packaged in a sealed foil pouch containing desiccant.
Slovenian: Aplikator, ki vsebuje vsadek, je pakiran v zatesnjenem mošnjičku iz folije, ki vsebuje sušilno sredstvo.
English: In cases in which the implant cannot be visualised, take a sterile cotton bud and lightly depress over the injection site to bring the implant into view.
Slovenian: Kadar ne vidite vsadka, uporabite sterilno vatno blazinico in nežno pritisnite na mesto injiciranja, da vsadek postane viden.
English: Other than those patients contraindicated (see section 4.3) where OZURDEX should not be used, OZURDEX should be used with caution and only following a careful risk benefit assessment.
Slovenian: Pri kontraindiciranih bolnikih (glejte poglavje 4.3) se zdravilo OZURDEX ne sme uporabljati, pri ostalih pa ga je treba uporabljati previdno in samo po temeljiti oceni tveganj in koristi.
English: The European Medicines Agency has waived the obligation to submit the results of studies with OZURDEX in all subsets of the paediatric population for retinal vascular occlusion and also for diabetic macular oedema (see section 4.2 for information on paediatric use).
Slovenian: OZURDEX za vse podskupine pediatrične populacije za retinalno žilno okluzijo in tudi za diabetični makularni edem (za informacije o uporabi pri pediatrični populaciji glejte poglavje 4.2).
English: Carefully remove the cap from the applicator.
Slovenian: Z aplikatorja previdno odstranite pokrovček.
English: The OZURDEX matrix slowly degrades to lactic acid and glycolic acid through simple hydrolysis, then further degrades into carbon dioxide and water.
Slovenian: Matriks zdravila OZURDEX se z navadno hidrolizo počasi razgradi na mlečno in glikolno kislino,
English: All OZURDEX injections will be given by an appropriately qualified eye doctor.
Slovenian: Vsako injiciranje zdravila OZURDEX bo opravil ustrezno usposobljen okulist.
English: The most frequently reported adverse reactions in patients who received OZURDEX were increased intraocular pressure (24.0 %) and conjunctival haemorrhage (14.7 %).
Slovenian: Neželena učinka pri bolnikih, ki so prejemali zdravilo OZURDEX, o katerih so poročali najpogosteje, sta bila zvišan očesni tlak (24,0 %) in krvavitev očesne veznice (14,7 %).
English: One patient treated with OZURDEX required incisional surgery (trabeculectomy) to manage the steroid-induced IOP elevation, 1 patient had a trabeculectomy owing to anterior chamber fibrin blocking the aqueous outflow leading to increased IOP, 1 patient had an iridotomy for narrow angle glaucoma and 1 patient had iridectomy due to cataract surgery.
Slovenian: Pri enem bolniku, zdravljenim z zdravilom OZURDEX, je bilo treba izvesti operacijo z rezanjem (trabekulektomijo) za odpravljanje zvišanega očesnega tlaka, ki so ga povzročili steroidi; pri enem bolniku je bila trabekulektomija izvedena zaradi fibrina v sprednjem prekatu, ki je blokiral odtok tekočine in s tem povečeval očesni tlak; pri enem bolniku je bila izvedena iridotomija glavkoma ozkega zakotja in pri enem bolniku je bila izvedena iridektomija zaradi operacije katarakte.
English: As for the initial treatment, peak response was seen at Day 60 in the open label phase.
Slovenian: Kot pri prvem zdravljenju so tudi pri odprti fazi največji odziv opazili na 60. dan.
English: Increased intraocular pressure (IOP) with OZURDEX peaked at day 60 and returned to baseline levels by day 180.
Slovenian: Zvišan očesni tlak (IOP) je dosegel najvišjo vrednost 60 dni po prejemu zdravila OZURDEX in se je vrnil na izhodiščno vrednost do 180. dneva.
English: One intravitreal implant in applicator.
Slovenian: En intravitrealni vsadek v aplikatorju.
English: Week 8
Slovenian: 8. teden
English: Immediately after injecting OZURDEX, use indirect ophthalmoscopy in the quadrant of injection to confirm successful implantation.
Slovenian: Takoj po injiciranju zdravila OZURDEX uporabite indirektno oftalmoskopijo v kvadrantu injiciranja,
English: The cumulative response rate curves (time to vitreous haze score of 0) were significantly different for the OZURDEX group compared to the Sham group (p < 0.001), with patients receiving dexamethasone showing an earlier onset and greater treatment response.
Slovenian: Krivulje hitrosti kumulativnega odziva (potreben čas za doseganje ničte stopnje motnosti steklovine) so bile pomembno različne pri skupini, ki je prejela zdravilo OZURDEX, in skupini, ki je prejela placebo (p < 0,001), pri čemer so pri bolnikih, ki so prejemali deksametazon, opazili zgodnejši in močnejši odziv na zdravljenje.
English: Sham N = 76
Slovenian: Placebo N = 76
English: The highest plasma concentration value of 0.102 ng/mL was observed in 1 subject from the 700 µg group.
Slovenian: Največjo koncentracijo v plazmi 0,102 ng/ml so opazili pri enem preizkušancu v skupini z odmerkom 700 µg.
English: The patient information pack should be provided in both the form of patient information booklet and an audio-CD that contain following key elements:
Slovenian: Paket informacij za bolnika je treba zagotoviti v obliki brošure in kot zvočno zgoščenko.
English: The reduction in vitreous haze was accompanied by an improvement in visual acuity.
Slovenian: Hkrati z zmanjšanjem motnosti steklovine so opazili tudi izboljšanje ostrine vida.
English: Day 60
Slovenian: 60. dan
English: RVO and uveitis
Slovenian: RVO in uveitis
English: Patients should be monitored following the injection to permit early treatment if an infection or increased intraocular pressure occurs (see section 4.4).
Slovenian: Po injiciranju je treba bolnike spremljati, da se lahko uvede zgodnje zdravljenje, če se pojavi okužba ali zvišan očesni tlak (glejte poglavje 4.4).
English: • How to prepare for OZURDEX treatment
Slovenian: • kako se pripraviti na zdravljenje z zdravilom OZURDEX,
English: In RVO, anti-coagulant therapy was used in 2% of patients receiving OZURDEX; there were no reports of haemorrhagic adverse events in these patients.
Slovenian: Pri okluziji retinalne vene je zdravljenje z antikoagulanti prejemalo 2 % bolnikov, ki so prejeli zdravilo OZURDEX; pri teh bolnikih niso poročali o neželenih dogodkih s krvavitvijo.
English: • inflammation of the posterior segment of the eye presenting as non-infectious uveitis
Slovenian: • vnetjem posteriornega dela očesa, ki se kaže kot nenalezljivi uveitis.
English: Studies in animals have shown teratogenic effects following topical ophthalmic administration (see section 5.3).
Slovenian: Študije na živalih so pokazale teratogene učinke po lokalnem očesnem nanosu (glejte poglavje 5.3).
English: Week 20
Slovenian: 20. teden
English: The proportion of patients with at least 15 letters improvement from baseline BCVA in the study eye at week 8 was more than 6-fold higher with OZURDEX (42.9%) compared to Sham (6.6%), p < 0.001.
Slovenian: Delež bolnikov, ki so dosegli izboljšanje za vsaj 15 črk od izhodiščne vrednosti pri najboljši vidni ostrini s korekcijo (BCVA) v preiskovanem očesu v 8. tednu, je bil več kot 6-krat večji pri zdravljenju z zdravilom OZURDEX (42,9 %) kot pri placebu (6,6 %), p < 0,001.
English: Do not advance the needle past the point where the sleeve of the applicator touches the conjunctiva.
Slovenian: Igle ne potiskajte več, ko se tulec aplikatorja dotakne očesne veznice.
English: The maximum treatment effect was observed at day 60 and the difference in the incidence of responders was statistically significant favouring OZURDEX compared with sham at all time points to day 90 following injection.
Slovenian: Največji učinek zdravljenja so opazili na 60. dan, incidenca bolnikov z odzivom pa je bila statistično pomembno večja v skupini, ki je prejemala zdravilo OZURDEX, kot v skupini, ki je prejemala placebo na vseh časovnih točkah do 90. dneva po injiciranju.
English: In some patients the eye pressure may increase with the possible development of glaucoma.
Slovenian: Pri nekaterih bolnikih se lahko po injiciranju zviša tlak v očesu, z možnostjo razvoja glavkoma.
English: In each Phase III study and the pooled analysis, the time to achieve ≥ 15 letters (3-line) improvement in BCVA cumulative response curves were significantly different with OZURDEX compared to sham (p < 0.001) with OZURDEX treated patients achieving a 3-line improvement in BCVA earlier than sham treated patients.
Slovenian: V obeh študijah 3. faze in analizi zbranih podatkov je bil čas do izboljšanja ≥ 15 črk (3 vrstice) na krivuljah hitrosti kumulativnega odziva pri BCVA pomembno različen pri skupini, ki je prejela zdravilo OZURDEX, od skupine, ki je prejela placebo (p < 0,001), saj so bolniki, ki so se zdravili z zdravilom OZURDEX, hitreje dosegli izboljšanje za 3 vrstice kot bolniki v skupini, ki je prejemala placebo.
English: Diabetic macular oedema is a swelling of the light-sensitive layer at the back of the eye called the macula.
Slovenian: Diabetični makularni edem je oteklina sloja, občutljivega na svetlobo, v ozadju očesa,
English: No mutagenicity, carcinogenicity, reproductive or developmental toxicity data are available for OZURDEX.
Slovenian: Za zdravilo OZURDEX ni podatkov o mutagenosti, kancerogenosti, vplivu na sposobnost razmnoževanja in razvoja.
English: The clinical safety of OZURDEX in patients with inflammation of the posterior segment of the eye presenting as non-infectious uveitis, has been assessed in a single, multicentre, masked, randomised study.
Slovenian: Klinično varnost zdravila OZURDEX pri bolnikih z vnetjem posteriornega dela očesa, ki se kaže kot nenalezljivi uveitis, so ocenili v enojni, multicentrični, slepi, randomizirani študiji.
English: They should not drive or use machines until this has resolved.
Slovenian: Dokler se to stanje ne popravi, ne smejo voziti in upravljati s stroji.
English: OZURDEX has not been studied in patients with renal impairment however no special considerations are needed in this population.
Slovenian: Zdravila OZURDEX niso preučevali pri bolnikih z okvaro delovanja ledvic, vendar pa pri tej populaciji ni potrebna posebna previdnost.
English: 59% of patients with a phakic study eye required cataract surgery by the 3 year final visit, with the majority performed in the 2nd and 3rd years.
Slovenian: 59 % bolnikov s fakično lečo na preiskovanem očesu je do zadnjega obiska v treh letih potrebovalo operacijo katarakte.
English: OZURDEX has not been studied in patients with hepatic impairment; however no special considerations are needed in this population.
Slovenian: Zdravila OZURDEX niso preučevali pri bolnikih z okvaro delovanja jeter, vendar pa pri tej populaciji ni potrebna posebna previdnost.
English: • macular oedema following either Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO) (see section 5.1)
Slovenian: • makularnim edemom po okluziji veje retinalne vene (BRVO-Branch Retinal Vein Occlusion) ali okluziji centralne retinalne vene (CRVO-Central Retinal Vein Occlusion) (glejte poglavje 5.1);
English: The proportion of patients with vitreous haze score of 0 in the study eye at week 8 (primary endpoint) was 4-fold higher with OZURDEX (46.8%) compared to Sham (11.8%), p < 0.001.
Slovenian: Delež bolnikov z ničto stopnjo motnosti steklovine v preiskovanem očesu v 8. tednu (primarni končni rezultat) je bil 4-krat večji pri zdravljenju z zdravilom OZURDEX (46,8 %) kot pri placebu (11,8 %),
English: In both studies, a total of 347 patients were randomized and received OZURDEX and 350 patients received sham.
Slovenian: V obeh študijah je bilo skupno naključno izbranih 347 bolnikov, ki so prejemali zdravilo OZURDEX, in 350 bolnikov, ki so prejemali placebo.
English: Dexamethasone has been shown to be teratogenic in mice and rabbits following topical ophthalmic application.
Slovenian: Pokazali so, da je deksametazon teratogen pri miših in kuncih po lokalnem očesnem nanosu.
English: High pressure in the eye, clouding at the back of the lens, bleeding into the inside of the eye*, worsening of vision*, difficulties in seeing clearly, detachment of the jelly inside the eye from the light-sensitive layer at the back of the eye (vitreous detachment)*, a feeling of spots in front of the eye (including ‘floaters')*, a feeling of looking through mist or fog*, inflammation of the eyelid, eye pain*, seeing flashes of light*, swelling of the layer over the white part of the eye*, redness of the eye*, headache
Slovenian: visok tlak v očesu, motnost na zadnjem delu očesne leče, krvavitev v notranjost očesa*, poslabšanje vida*, nejasen vid, odstop steklovine od plasti, občutljive za svetlobo, v ozadju očesa (odstop steklovine)*, občutek plavajočih pik pred očmi (plavajoče motnjave)*, občutek gledanja skozi meglo*, vnetje veke, bolečina v očesu*, bliskanje pred očmi*, otekanje plasti nad beločnico*, pordelost očesa*,